BMO Argues For Biogen As Most Logical Takeover Target For Pfizer

Commenting on "significant market speculation" that Pfizer is preparing to execute a large M&A deal, BMO Capital analyst Alex Arfaei argued that he sees a strong strategic rationale for a merger with Biogen.